With Eos Merger, Pharmacopeia s Drug Discovery Gain also Helps Accelrys | GenomeWeb

Pharmacopeia and Eos Biotechnology announced plans last week to merge in a stock-for-stock transaction valued at approximately $197 million. While the merger was initiated primarily to boost Pharmacopeia’s slumping drug discovery revenues, Pharmacopeia’s Accelrys software unit also stands to benefit from the deal, according to executives at the companies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.